Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Bayer second-quarter core earnings up 3.9 percent thanks to Monsanto takeover

Published 05/09/2018, 07:54
Updated 05/09/2018, 07:54
© Reuters. FILE PHOTO: The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal, Germany

By Ludwig Burger

FRANKFURT (Reuters) - Bayer (DE:BAYGn) eked out a 3.9 percent gain in underlying core earnings for the quarter, as a rebound in crop protection and the addition of U.S. seeds maker Monsanto (NYSE:MON) offset weak consumer healthcare sales and unfavourable currency effects.

Second-quarter earnings before interest, tax, depreciation and amortisation (EBITDA), adjusted for one-off items, rose to 2.34 billion euros (£2.11 billion), the company reported on Wednesday, slightly below analyst estimates in a Reuters poll for 2.44 billion on average.

The $63 billion takeover of Monsanto will make Bayer as reliant on farming supplies as on pharmaceuticals for earnings. It is in the midst of an overhaul of its drug research and development activities as it faces calls to beef up its pharma development pipeline.

Adjusted EBITDA at the enlarged Crop Science division, now the world's largest supplier of seeds and pesticides, almost doubled to a better-than-expected 631 million euros, helped by a recovery in Brazil and as Monsanto, part of Bayer since June 7, contributed 70 million.

Earnings at the Consumer Health unit, meanwhile, dropped 18.5 percent as a weak U.S. dollar weighed on the value of overseas sales and revenues of brands such as Claritin against allergies or the Coppertone sun screen declined further.

Bayer has suffered from U.S. consumers switching from established drugstores to online shops to hunt for bargains.

Bayer now expects EBITDA before special items to increase by a low- to mid-single-digit percentage in 2018. It had previously forecast a decline by a low-single-digit percentage, at the time excluding the effect of the Monsanto acquisition.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

But adjusted core earnings per share would likely decline to between 5.70 and 5.90 euros, down from 6.64 a year earlier, because Bayer closed the Monsanto deal closed later than anticipated, missing out on a first half that is typically much stronger for Monsanto than the second.

Bayer said it would still pay out a dividend per share for 2018 that was at least at the year-earlier level, more than its dividend payout policy of 30 to 40 percent of core earnings per share would command.

"We expect the combined business to deliver successful performance and want to enable our shareholders to share in our company’s success," Chief Executive Werner Baumann said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.